An immunotherapy for type 1 diabetes won orphan drug status from the FDA this week as it enters phase II trials. Drugmaker DiaVacs says DV-0100 halts the autoimmune reaction against islet cells by modifying a patient’s own dendritic cells and injecting them back into the body.

Read more